Edgar Filing: IMMUNOGEN INC - Form 3

IMMUNOGEN INC

Form 3

December 16, 2016

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

OMB Number:

3235-0104

Expires:

January 31, 2005

Estimated average burden hours per

response...

0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF

SECURITIES

(Print or Type Responses)

1. Name and Address of Reporting

Person *

A Wingrove Theresa

(Last)

(First)

(Middle)

2. Date of Event Requiring 3. Issuer Name and Ticker or Trading Symbol

Statement

(Month/Day/Year)

12/09/2016

IMMUNOGEN INC [IMGN]

(Check all applicable)

VP of Regulatory Affairs

4. Relationship of Reporting Person(s) to Issuer

5. If Amendment, Date Original

Filed(Month/Day/Year)

C/O IMMUNOGEN, INC., Â 830

WINTER STREET

(Street)

Director _X__ Officer

10% Owner Other (give title below) (specify below)

6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting

Person

Form filed by More than One

Reporting Person

WALTHAM, MAÂ 02451

(City) (State) (Zip)

1. Title of Security

(Instr. 4)

Table I - Non-Derivative Securities Beneficially Owned 2. Amount of Securities

Beneficially Owned (Instr. 4)

Ownership Form: Direct (D)

or Indirect (I) (Instr. 5)

4. Nature of Indirect Beneficial Ownership

(Instr. 5)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)

2. Date Exercisable and **Expiration Date** (Month/Day/Year)

3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)

4. Conversion or Exercise Price of

5. Ownership Form of Derivative

6. Nature of Indirect Beneficial

Ownership

(Instr. 5)

Date Exercisable Expiration

Date

Title

Amount or Number of Shares

Security: Derivative Security Direct (D) or Indirect (I)

1

Edgar Filing: IMMUNOGEN INC - Form 3

						(Instr. 5)	
Stock Option (right to buy)	01/18/2012(1)	01/18/2021	Common Stock	37,500	\$ 9.85	D	Â
Stock Option (right to buy)	07/22/2012(2)	07/22/2021	Common Stock	20,000	\$ 15.2	D	Â
Stock Option (right to buy)	07/20/2013(3)	07/20/2022	Common Stock	40,000	\$ 15.83	D	Â
Stock Option (right to buy)	07/16/2014(4)	07/16/2023	Common Stock	40,000	\$ 19.02	D	Â
Stock Option (right to buy)	07/17/2015(5)	07/17/2024	Common Stock	40,000	\$ 10.79	D	Â
Stock Option (right to buy)	07/13/2016(6)	07/13/2025	Common Stock	48,000	\$ 16.72	D	Â
Stock Option (right to buy)	06/01/2017(7)	06/01/2026	Common Stock	4,000	\$ 5.75	D	Â
Stock Option (right to buy)	07/18/2017(8)	07/18/2026	Common Stock	50,000	\$ 3.05	D	Â
Stock Option (right to buy)	09/30/2017(9)	09/30/2026	Common Stock	38,000	\$ 2.68	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships					
	Director	10% Owner	Officer	Other		
Wingrove Theresa C/O IMMUNOGEN, INC. 830 WINTER STREET WALTHAM. MA 02451	Â	Â	VP of Regulatory Affairs	Â		

Signatures

/s/ Craig Barrows, attorney in fact 12/16/2016

**Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) All options exercisable as of filing date.
- (2) All options exercisable as of filing date.
- (3) All options exercisable as of filing date.
- (4) All options exercisable as of filing date.
- (5) 26,667 options exercisable as of filing date and 13,333 shares exercisable commencing on July 17, 2017.

Reporting Owners 2

Edgar Filing: IMMUNOGEN INC - Form 3

- (6) 16,000 options exercisable as of filing date, 16,000 shares exercisable commencing on July 13, 2017, and 16,000 shares exercisable commencing on July 13, 2018.
- (7) Exercisable as to 1,334 shares commencing on June 1, 2017, 1,333 shares commencing on June 1, 2018, and 1,333 shares commencing on June 1, 2019.
- (8) Exercisable as to 16,667 shares commencing on July 18, 2017, 16,667 shares commencing on July 18, 2018, and 16,666 shares commencing on July 18, 2019.
- (9) Exercisable as to 12,667 shares commencing on September 30, 2017, 12,667 shares commencing on September 30, 2018, and 12,666 shares commencing on September 30, 2019.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.